Stephen J. Forman - 30 Jun 2022 Form 4 Insider Report for LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT)

Role
Director
Signature
/s/ Stephen Forman
Issuer symbol
LIXT
Transactions as of
30 Jun 2022
Net transactions value
$0
Form type
4
Filing time
03 Aug 2022, 16:45:54 UTC
Previous filing
02 Jul 2021
Next filing
07 Jul 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIXT Options to Purchase Common Stock Award $0 +100,000 $0.000000 100,000 30 Jun 2022 Common 100,000 $0.7446 Direct F1
holding LIXT Options to Purchase Common Stock 100,000 30 Jun 2022 Common 100,000 $3.03 Direct
holding LIXT Options to Purchase Common Stock 50,000 30 Jun 2022 Common 50,000 $3.21 Direct
holding LIXT Warrants to Purchase Common Stock 21,053 30 Jun 2022 Common 21,053 $5.70 By Stephen Forman Living Trust
holding LIXT Options to Purchase Common Stock 8,333 30 Jun 2022 Common 8,333 $0.9000 Direct
holding LIXT Options to Purchase Common Stock 8,333 30 Jun 2022 Common 8,333 $6.60 Direct
holding LIXT Warrants to Purchase Common Stock 16,667 30 Jun 2022 Common 16,667 $6.00 By Stephen Forman Living Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Effective June 30, 2022, the reporting person was granted stock options to purchase an aggregate of 100,000 shares, vesting on the last day of each subsequent quarter until fully vested (e.g. vesting to start on September 30, 2022).